Elsevier

Dermatologic Clinics

Volume 32, Issue 4, October 2014, Pages 549-553
Dermatologic Clinics

Managing Hyperhidrosis: Emerging Therapies

https://doi.org/10.1016/j.det.2014.06.003Get rights and content

Section snippets

Key points

  • Topical botulinum toxin A can be delivered through intact skin.

  • Topical anticholinergic agents may provide efficacy with decreased adverse effects.

  • Devices delivering energy such as lasers, ultrasound, and radiofrequency may reduce focal sweat.

  • Limited data are available, and more research is needed.

Summary

There is still a need for new therapies for the treatment of primary and secondary forms of hyperhidrosis. Understanding the location of the sweat glands and the pharmacology of sweat will help to drive new developments.

First page preview

First page preview
Click to open first page preview

References (17)

  • R.W. Brobst et al.

    Ulthera: initial and six month results

    Facial Plast Surg Clin North Am

    (2012)
  • C. Jacob

    Treatment of hyperhidrosis with microwave technology

    Semin Cutan Med Surg

    (2013)
  • D.A. Glaser et al.

    A randomized, blinded clinical evaluation of a novel microwave device for treating axillary hyperhidrosis: the dermatologic reduction in underarm perspiration study

    Dermatol Surg

    (2012)
  • R.G. Glogau

    Topically applied botulinum toxin type A for the treatment of primary axillary hyperhidrosis: results of a randomized, blinded, vehicle-controlled study

    Dermatol Surg

    (2007)
  • A. MacKenzie et al.

    Topical glycopyrrolate for axillary hyperhidrosis

    Br J Dermatol

    (2013)
  • J.Y. Luh et al.

    Craniofacial hyperhidrosis successfully treated with topical glycopyrrolate

    South Med J

    (2002)
  • G.M. Garnacho Saucedo et al.

    Therapeutic hotline: topical glycopyrrolate: a successful treatment for craniofacial hyperhidrosis and eccrine hidrocystomas

    Dermatol Ther

    (2010)
  • J.E. Shaw et al.

    A randomised controlled trial of topical glycopyrrolate, the first specific treatment for diabetic gustatory sweating

    Diabetologia

    (1997)
There are more references available in the full text version of this article.

Cited by (12)

  • The etiology, diagnosis, and management of hyperhidrosis: A comprehensive review: Therapeutic options

    2019, Journal of the American Academy of Dermatology
    Citation Excerpt :

    Topical glycopyrrolate (0.5% to 4% solution, gel, cream, or pads) and 3% topical oxybutynin are the most commonly used topical anticholinergic agents.36,37 Adverse effects include skin irritation, pruritus, headache, dizziness, sore throat, mydriasis, dry mouth, constipation, and nasopharyngitis.34,36,38-41 BTX is a common effective injectable medication for HH, but its large molecular size prevents it from crossing intact skin.42

  • The efficacy of oral anticholinergics for sympathetic overactivity in a thoracic surgery clinic

    2016, Journal of Thoracic and Cardiovascular Surgery
    Citation Excerpt :

    Most notably, botulinum toxin has proved an effective albeit temporary and costly therapy. Many ingenious local device therapies also have been tested, including fractional radiofrequency, iontophoresis, lasers, and ultrasound but have established mixed results.6 The most limiting aspects of topical and localized therapies are their transient efficacy and the challenge to treating multifocal disease.

  • Treatment of Axillary hyperhidrosis

    2022, Journal of Cosmetic Dermatology
View all citing articles on Scopus

Disclosure: D.A. Glaser has served as advisor for Allergan, Galderma, Miramar Labs, and Unilever. She has been an investigator and received research grants from Allergan, Miramar Labs, and Ulthera. T.A. Galperin has nothing to disclose.

View full text